Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The U.S. government and HIV drugmaker Gilead Sciences continue to fight over patents for Truvada and Descovy as PrEP.
Who owns the rights to PrEP? The U.S. government or the pharma giant?
Plus: Tell your representatives to support the PrEP Access and Coverage Act. Here’s how.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.
This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
Activists want future and retroactive royalties to pay for a national PrEP program.
If the price is lowered with a generic version of PrEP, activists say, “we could end the HIV epidemic without a vaccine.”
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.
Experts say taking away the patent for the HIV/AIDS and hepatitis B drug will open the door for cheaper versions of the drug.
New generic HIV medications could save the U.S. health care system $1 billion a year, but may also raise the likelihood of treatment failure.
To help people with HIV who cannot afford their antiretroviral medications, former President Bill Clinton has proposed a new plan.
World political and health leaders gathered in June at the United Nations for
a special session of the General Assembly focusing on HIV...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.